Clinical & Experimental Ophthalmology

Biography

Biography: Ronald Sanchez Avila

Abstract

Purpose: To evaluate the effectiveness that has the eye drops plasma rich in growth factors (PRGF) for the Treatment of Ocular Surface Diseases (ESD) in patients with glaucoma. Material & Methods: Longitudinal, observational and descriptive study included 6 patients diagnosed with open-angle glaucoma who received surgical treatment (EPNP and or trabeculectomy) and medical (1-3 hypotensive eye drops) to control IOP (Intraocular pressure) which developed different ESD (Dry Eye Syndrome: Evaporative and or production shortfall, corneal ulcers, limbal stem cell deficiency, viral keratitis) unresponsive to conventional treatment. The variables analyzed were: VAS (Visual Analog Scale: Frequency and severity of symptoms), dry eye Psychometric Survey (OSDI: Ocular Surface Disease Index) Visual acuity (VA) far (LogMAR), tear breakup time (TBUT), Schirmer test and IOP; such measures were taken before starting treatment with PRGF, the next week, month and in subsequent visits, patients were followed for nearly a year. Results: Patients was aged between 58 and 79 years (mean age, 71±7.2). Treatment cycles with PRGF were between 2 and 6 (1 cycle=6 weeks). They target the AV (logMAR) improved 44.5% (p=0.012), the test OSDI decreased 58.5% (p=0.027), the VAS in frequency was decreased 53.5% (p=0.026), the VAS in severity decreased 44.57% (p=0.027) and IOP decreased by 16.5% (p=0.010); TBUT and Schirmer test improving trend was also evident. One patient reported itching in both eyes as a side effect (SE) but continued with the treatment until the end and the remaining patients reported no SE. Conclusions: In patients with glaucoma and have ESD unresponsive to conventional treatments can now use the eye drops PRGF showing clinical improvement and reduction of IOP.